© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.
After identifying these priorities, Gilead Sciences launched its TRANScend Fund. Here’s how to apply for a grant.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Nationwide, significant proportions of PrEP-using populations do not stay on Truvada for long.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
Researchers compared data on more than 9,000 people with HIV who took either version of tenofovir.
Stop by during the Oklahoma City Pride Festival on June 22 for an HIV Test, a visit with a doc and a script for PrEP.
Nearly $200 million of the pledge will go to DREAMS programs in Africa and the Caribbean.
The proposal allows pharmacies to dispense a first-time 30-day supply of the HIV prevention pill without a script.
In the form of direct quotes from the participants
Truvada and Descovy are both highly effective and generally safe options for HIV prevention.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
